Spectrum of Cardiac Lesions in Behcet Disease A Series of 52 Patients and Review of the Literature

被引:182
作者
Geri, Guillaume [2 ]
Wechsler, Bertrand [2 ]
Du Le Thi Huong [2 ]
Isnard, Richard [3 ]
Piette, Jean-Charles [2 ]
Amoura, Zahir [2 ]
Resche-Rigon, Mathieu [4 ]
Cacoub, Patrice [2 ]
Saadoun, David [1 ,2 ]
机构
[1] Univ Paris 06, Hop La Pitie Salpetriere, Dept Internal Med, CNRS,INSERM,UPMC,U959,UMR 7211, F-75013 Paris, France
[2] Grp Hosp Pitie Salpetriere, Assistance Publ Hop Paris, Serv Med Interne 2, F-75634 Paris, France
[3] Grp Hosp Pitie Salpetriere, Assistance Publ Hop Paris, Serv Cardiol, F-75634 Paris, France
[4] Grp Hosp St Louis, Assistance Publ Hop Paris, Dept Biostat, Paris, France
关键词
ACUTE MYOCARDIAL-INFARCTION; CEREBRAL VENOUS THROMBOSIS; LEFT-VENTRICULAR ANEURYSM; CARDIOVASCULAR INVOLVEMENT; ACUTE PERICARDITIS; ENDOMYOCARDIAL FIBROSIS; INTRACARDIAC THROMBUS; DIASTOLIC DYSFUNCTION; ARTERY INVOLVEMENT; PROGNOSTIC-FACTORS;
D O I
10.1097/MD.0b013e3182428f49
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Cardiac abnormalities in patients with Behcet disease (BD) include pericarditis, myocarditis, endocarditis with valvular regurgitation, intracardiac thrombosis, endomyocardial fibrosis, coronary arteritis with or without myocardial infarction, and aneurysms of the coronary arteries or sinus of Valsalva. Data regarding the clinical spectrum, prevalence, and outcome of cardiac lesions in BD are lacking. In this study, we report the main characteristics, treatment, and long-term outcomes of 52 patients with cardiac lesions from a cohort of 807 (6%) BD patients. Forty-five (86.5%) patients were male, with a mean (+/-SD) age at BD diagnosis of 29.3 +/- 10.3 years. Cardiac involvement was the first feature of BD in 17 (32.7%) patients. Cardiac lesions included pericarditis (n = 20; 38.5%), endocarditis (mostly aortic insufficiency) (n = 14; 26.9%), intracardiac thrombosis (n = 10; 19.2%), myocardial infarction (n = 9; 17.3%), endomyocardial fibrosis (n = 4; 7.7%) and myocardial aneurysm (n = 1; 1.9%). Patients with cardiac involvement were more frequently male (86.5% vs. 64.9%; p < 0.01) and had more arterial (42.3% vs. 11.1%; p < 0.01) and venous lesions (59.6% vs. 35.8%; p < 0.01) compared to those without cardiac manifestations. Factors associated with complete remission of cardiac involvement were treatment regimens with oral anticoagulants, immunosuppressants, and colchicine. The 5-year survival rate was 83.6% and 95.8% (p = 0.03) in BD patients with and without cardiac involvement, respectively. After a median (Q1-Q3) follow-up of 3.0 (1.75-4.2) years, 8 patients had died, in 3 cases directly related to cardiac involvement. In conclusion, cardiac lesions affected 6% of our large cohort of BD patients. The prognosis of cardiac involvement in BD is poor and improves with oral anticoagulation, immunosuppressive therapy, and colchicine.
引用
收藏
页码:25 / 34
页数:10
相关论文
共 73 条
  • [1] Behcet's disease and cardiovascular involvement
    Atzeni, F
    Sarzi-Puttini, P
    Doria, A
    Boiardi, L
    Pipitone, N
    Salvarani, C
    [J]. LUPUS, 2005, 14 (09) : 723 - 726
  • [2] Aortic valve replacement in Behcet's disease: surgical modification to prevent valve detachment
    Azuma, Takashi
    Yamazaki, Kenji
    Saito, Satoshi
    Kurosawa, Hiromi
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 36 (04) : 771 - 772
  • [3] Evaluation of left ventricular diastolic dysfunction with conventional and current Doppler techniques in Behcet's disease
    Baris, Nezihi
    Okan, Taha
    Gurler, Oguz
    Akdeniz, Bahri
    Turker, Sonay
    Ilknur, Turna
    Akkoc, Nurullah
    Goldeli, Ozhan
    [J]. CLINICAL RHEUMATOLOGY, 2006, 25 (06) : 873 - 876
  • [4] Cardiac thrombosis in a patient with Behcet's disease: Two years follow-up
    Basaran, Y
    Degertekin, M
    Direskeneli, H
    Yakut, C
    [J]. INTERNATIONAL JOURNAL OF CARDIAC IMAGING, 2000, 16 (05): : 377 - 382
  • [5] Baykan M, 2001, Heart, V85, pE7, DOI 10.1136/heart.85.4.e7
  • [6] Ben Dhaou B, 2006, 12 INT C BEHC DIS LI
  • [7] Bennis A, 1996, ANN MED INTERNE, V147, P126
  • [8] Beyranvand MR, 2009, ARCH IRAN MED, V12, P313
  • [9] BINAK K, 1980, J RHEUMATOL, V7, P578
  • [10] BLETRY O, 1988, PRESSE MED, V17, P2388